Cencora to acquire Retina Consultants of America for up to $5.1 Billion

News
Article

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora.

(Image Credit: AdobeStock)

(Image Credit: AdobeStock)

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora for approximately $4.6 billion in cash and up to $500 million in aggregate contingent consideration, subject to the successful completion of certain predefined business objectives.The transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.1

Retina Consultants of America is a network of retina practices that provide exceptional care across the nation. The retina specialists and surgeons within its network are recognized as leaders in the retina space and among the highest level of retina care providers in the United States, providing advanced care for macular degeneration, diabetic retinopathy, geographic atrophy, and all conditions of the retina.1

Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies, and the communities that the company serves. Its mission is to deliver superior returns to its partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients.1

Reference:
1. Retina Consultants of America To Be Acquired By Cencora For Up To $5.1 Billion. Goodwin. November 6, 2024. November 11, 2024. https://www.goodwinlaw.com/en/news-and-events/news/2024/11/announcements-privateequity-hltc-goodwin-advises-retina-and-webster-in-sale-of-rca-to-cencora
Recent Videos
WIO 2024: An educator's perspective on shattering glass ceilings in ophthalmology
Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care at WIO 2024
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
© 2024 MJH Life Sciences

All rights reserved.